

Gleevec® (imatinib) - New warning

- On September 6, 2017, the FDA approved an update to the Warnings and Precautions section of the Gleevec (imatinib) drug label regarding the risk of renal toxicity.
- Gleevec is approved for multiple oncology indications, including newly diagnosed Philadelphia (Ph)positive chronic myeloid leukemia (CML); Ph-positive CML in blast crisis, accelerated phase, or
 chronic phase after interferon-alpha therapy; adult patients with Ph-positive acute lymphoblastic
 leukemia (ALL); pediatric patients with Ph-positive ALL; myelodysplastic/myeloproliferative diseases;
 aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic
 leukemia; dermatofibrosarcoma protuberans; KIT-positive gastrointestinal stromal tumors (GIST);
 and adjuvant treatment of GIST.
- A decline in renal function may occur in patients receiving Gleevec.
 - The median estimated glomerular filtration rate values in patients on Gleevec 400 mg daily for newly-diagnosed CML (four randomized trials) and malignant GIST (one single-arm trial) declined from a baseline value of 85 ml/min/1.73m² (n = 1190) to 75 ml/min/1.73m² at 12 months (n = 1082) and 69 ml/min/1.73m² at 60 months (n = 549).
 - Healthcare providers should evaluate renal function prior to initiating Gleevec and monitor during therapy, with attention to risk factors for renal dysfunction such as pre-existing renal impairment, diabetes mellitus, hypertension, and congestive heart failure.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.